Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that androsterone glucuronate (ADT-G) was the only androgenic metabolite sensitive to detecting differences between adult women with acne and controls, and its levels decreased with systemic treatment.

This study found that bolandiol increased lean body mass and bone mineral density in castrate adult male rats, exhibiting tissue selectivity and acting through multiple receptor pathways with less potency compared to other androgens.

The researchers reported that compounds 11 to 13 derived from Westphalen-type steroids showed strong antiandrogenic activity in vivo, though their effects could not be attributed to 5α-reductase inhibition or androgen receptor binding.

In this study, oral dienogest combined with ethinylestradiol provided effective contraception with a Pearl Index of approximately 0.2 and improved androgenic symptoms without significant metabolic effects.

This study found that a daily dose of 50 mg DHEA only slightly increased the urinary testosterone/epitestosterone ratio for a short period, without exceeding the IOC's acceptable limit.

A new compound was made that might help treat diseases related to male hormones.

This study found that cyproterone acetate with ethynyl estradiol improved acne and seborrhea within 3–6 months in women, but had less satisfactory results for alopecia and hirsutism.

This study reports that newly synthesized steroidal trienones exhibit higher 5α-reductase inhibitory activity than dienones in various biological models, suggesting potential use in treating androgen-dependent diseases.

This article reviews the clinical signs, diagnostic approaches, and treatment options for hyperandrogenism in women, focusing on hirsutism and specifies that cyproterone acetate is effective for severe cases, but reports no new clinical results.

This study evaluated novel steroid compounds for their ability to inhibit 5α-reductase, showing that compound 16a significantly reduced rat prostate weight more than epristeride and exhibited excellent in vitro inhibitory potency, indicating its potential as a lead candidate for further benign prostatic hyperplasia drug research.

In this study, insulin resistance in polycystic ovary syndrome was highly correlated with unbound testosterone and sex hormone-binding globulin, rather than luteinizing hormone or peripheral androgen metabolism.

This review discusses the potential role of steroid 5α-reductase inhibitors in treating neuropsychiatric disorders related to dopaminergic hyperreactivity but reports no new clinical results.

This study found that dutasteride pretreatment reduced certain sedative effects of alcohol and may decrease drinking behavior in adult men, likely by impacting neuroactive steroid levels.

This article discusses whether testosterone's metabolism to 5α-dihydrotestosterone is necessary for androgenic effects in the skin but reports no new experimental results.

Finasteride effectively lowers specific hormone levels, helping monitor treatment progress.

In this study, combining flutamide with finasteride showed additive effects in reducing tumor and prostate growth in a mouse model predictive of androgen-sensitive prostate cancer.

This study found that both finasteride and metformin effectively reduced androgen levels and insulin resistance parameters in women with PCOS, without clear evidence of one treatment being superior.

In this study, biochemical and clinical hyperandrogenism in PCOS were found to be distinct entities with no strong androgen correlation to clinical symptoms like acne or hirsutism.

Androgens like testosterone affect skin health and can lead to conditions such as acne and hair loss, with various treatments available.

The document concludes that a compound with potential for treating prostate cancer and hair loss was successfully made and its detailed structure was confirmed.

This study found that several dehydroepiandrosterone ester derivatives effectively reduced prostate and seminal vesicle weight in gonadectomized hamsters treated with testosterone, demonstrating potential antiandrogen effects comparable to Finasteride.

This study found that women with PCOS displayed significantly higher activity of 5alpha-reductase, suggesting an additional role for liver and peripheral tissues in their androgen excess.

A new compound that could treat various androgen-related conditions was created and analyzed.

This study reported that while no synthesized compounds surpassed finasteride in 5α-reductase inhibitory activity, certain 4-azasteroid-2-oximes exhibited notable inhibition.

This study found that several new pregnane derivatives, especially steroids 16 and 19, demonstrated higher antiandrogenic activity on male hamster models than the commonly used finasteride.

This study investigated various synthesized 5-reductase inhibitors and found that compound 6 had the highest anti-androgenic activity and receptor affinity compared to finasteride, showing potential due to its improved efficacy and bioavailability for further research in treating lower urinary tract symptoms.

This study found that topical application of hair lotion containing 17α-estradiol may reduce androgenetic hair loss, as 63% of treated patients showed a decrease in telogen hairs compared to 37% in the control group.

This study found that castration-resistant prostate cancers resistant to CYP17A1 inhibitors may still depend on steroids and could respond to therapies targeting de novo intratumoral steroid synthesis.